Abstracts Archive - Page 776 of 2425 - ACR Meeting Abstracts

Abstract Number: 1820 • ACR Convergence 2020
Serum α-Klotho Is Decreased in Older Systemic Lupus Erythematosus Patients and Correlate with Markers of Disease Activity
Margaret Markiewicz¹, Dayvia Russell² and Jim Oates¹, ¹Medical University of South Carolina, Charleston, SC, Charleston, SC, ².Research Services, Ralph H. Johnson VA Medical Center, Charleston, SC,, Charleston
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, debilitating autoimmune disease characterized by heterogeneous, multiorgan involvement with female predominance. Lupus nephritis is one of the…
Abstract Number: 1821 • ACR Convergence 2020
Early Assessment of Left Ventricular Assessment Using Speckle Tracking Echocardiography and It´s Relationship with Insulin Resistance in Women with Systemic Lupus Erythematosus
Pamela Munguía-Realpozo¹, Claudia Mendoza-Pinto², Socorro Méndez-Martínez², Liliana Pérez-Aquino³, Ivet Etchegaray-Morales¹ and Mario Garcia-Carrasco², ¹Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla, Puebla, Mexico, ²Instituto Mexicano del Seguro Social, Puebla, Puebla, Mexico, ³Facultad de Medicina, Beneméria Universidad Autónoma de Puebla, Puebla, Puebla, Mexico
Background/Purpose: Systemic lupus erythematosus patients (SLE) have increased cardiovascular risk. Patients with SLE are associated with significant alterations in cardiac structure and function as demonstrated…
Abstract Number: 1822 • ACR Convergence 2020
Serum Proteomics from a Phase III, Randomized, Placebo-Controlled Study of Patients with Active Lupus Nephritis: Correlation with Baseline Disease Characteristics and Response to Therapy
Shiliang Wang¹, Richard Furie², Mary Anne Dooley³, David Wofsy⁴, Tsutomu Takeuchi⁵, Ana Malvar⁶, Andrea Doria⁷, Juanita Romero-Díaz⁸, Tak Mao Chan⁹, Gerald Appel¹⁰, David Jayne¹¹, Sarah Hu¹², Sheng Gao¹³ and Michael Maldonado¹², ¹Bristol-Myers Squibb Company (at the time of analysis), Princeton, NJ, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³University of North Carolina, Chapel Hill, NC, ⁴University of California San Francisco, San Francisco, CA, ⁵Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ⁶Organizacion Medica de Investigacion, Buenos Aires, Argentina, ⁷University of Padua, Padua, Italy, ⁸Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁹University of Hong Kong, Hong Kong, Hong Kong, ¹⁰Columbia University Medical Center, New York, NY, ¹¹Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ¹²Bristol-Myers Squibb Company, Princeton, NJ, ¹³Bristol-Myers Squibb Company (at the time of analysis), Princeton, NY
Background/Purpose: The ALLURE study compared efficacy and safety of abatacept (ABA) vs placebo (PBO) on background MMF and CS for the treatment of active proliferative…
Abstract Number: 1823 • ACR Convergence 2020
Mycophenolate Mofetil for Systemic Lupus Erythematosus: Our 20-year Experience
Michael Trevisonno¹, Alexander Hall¹, Cristina Sorrento¹ and Ellen M Ginzler², ¹State University of New York Downstate Medical Center, Brooklyn, NY, ²SUNY Downstate Health Sciences University, Brooklyn
Background/Purpose: Mycophenolate Mofetil (MMF) has been long used in the treatment of systemic lupus Erythematosus (SLE). Despite its proven effectiveness, particularly in the treatment of…
Abstract Number: 1824 • ACR Convergence 2020
Selective Expansion of Regulatory T Cells in Patients with Systemic Lupus Erythematosus by a Novel IL-2 Conjugate, NKTR-358
Christie Fanton¹, Richard Furie², Neha Dixit¹, Cat Haglund¹, Lin Lu¹, Suresh Siddhanti¹, Vishala Chindalore³, Robert Levin⁴, Isam Diab⁵, Brian Kotzin¹ and Jonathan Zalevsky¹, ¹Nektar Therapeutics, San Francisco, CA, ²Division of Rheumatology, Northwell Health, Great Neck, NY, ³Pinnacle Research Group, Anniston, AL, ⁴Clinical Research of West Florida, Clearwater, FL, ⁵Paramount Medical Research and Consulting, Middleburg Heights, OH
Background/Purpose: Treg dysfunction and impaired IL-2 production have been implicated as key immunological defects in the breakdown of immune self-tolerance in SLE. Low-dose IL-2 can…
Abstract Number: 1825 • ACR Convergence 2020
Risk Factors for Antimalarial-Induced Retinal Toxicity in Systemic Lupus Erythematosus and Other Rheumatic Diseases
Gemma Cramarossa¹, Hsin-Yen Liu² and Janet Pope³, ¹Western University, Kleinburg, ON, Canada, ²Western University, London, ON, Canada, ³Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada
Background/Purpose: Hydroxychloroquine (HCQ) and chloroquine (CQ) are antimalarial (AM) medications prescribed for a variety of rheumatic diseases, including systemic lupus erythematosus (SLE). Many patients will…
Abstract Number: 1826 • ACR Convergence 2020
Maintenance of Efficacy and Safety and Reduction of BILAG Flares with Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: 2-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study
Ronald van Vollenhoven¹, Bevra Hahn², George Tsokos³, Peter Lipsky⁴, Robert Gordon⁵, Kaiyin Fei⁶, Kim Hung Lo⁷, Marc Chevrier⁸, Qing Zuraw⁹, Pamela Berry¹⁰, Chetan Karyekar¹⁰ and Shawn Rose¹¹, ¹Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²University of California Los Angeles, Encino, CA, ³Division of Rheumatology & Clinical Immunology/Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, ⁴RILITE Foundation, Charlottesville, VA, ⁵Janssen Research & Development, LLC, Chester Springs, PA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Janssen Research & Development, LLC, Spring House, ⁸Janssen Research & Development, LLC, Collegeville, PA, ⁹Janssen Research & Development, LLC, Wayne, PA, ¹⁰Janssen Global Services, LLC, Horsham, PA, ¹¹Janssen Research & Development, LLC, Princeton Junction, NJ
Background/Purpose: Both IL-12 and IL-23 have been implicated in the pathogenesis of SLE. In a phase 2 study, treatment with the anti-IL-12/23 p40 monoclonal antibody…
Abstract Number: 1827 • ACR Convergence 2020
Flare Reduction and Oral Corticosteroid Taper in Patients with Active SLE Treated with Anifrolumab in 2 Phase 3 Trials
Richard Furie¹, Eric Morand², Anca Askanase³, Ed Vital⁴, Joan Merrill⁵, Rubana Kalyani⁶, Gabriel Abreu⁷, Lilia Pineda⁶ and Raj Tummala⁶, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, ²Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ³Columbia University College of Physicians and Surgeons, New York, ⁴University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, ⁷BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: Objectives of long-term SLE management are not only to reduce disease activity, but also to prevent flares and minimize exposure to oral corticosteroids (OCS),…
Abstract Number: 1828 • ACR Convergence 2020
Comprehensive Efficacy of Anifrolumab Across Organ Domains in Patients with Active SLE: Pooled Data from 2 Phase 3 Trials
Eric Morand¹, Richard Furie², Ian Bruce³, Ed Vital⁴, Maria Dall'Era⁵, Emmanuelle Maho⁶, Lilia Pineda⁷ and Raj Tummala⁷, ¹Monash University, Melbourne, Australia, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, ³Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Division of Rheumatology, University of California, San Francisco, CA, ⁶BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁷BioPharmaceuticals R&D, AstraZeneca, Gaithersburg
Background/Purpose: SLE is a heterogeneous autoimmune disease with clinical manifestations across multiple organ systems. In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab treatment resulted…
Abstract Number: 1829 • ACR Convergence 2020
Lupus Disease Activity After Cessation of Anifrolumab Treatment During the Phase 2b MUSE Trial Follow-up Period
Richard Furie¹, Kenneth Kalunian², Joan Merrill³, Gabriel Abreu⁴ and Raj Tummala⁵, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, ²School of Health Sciences, University of California, La Jolla, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg
Background/Purpose: In the randomized, double-blind, phase 2b MUSE trial, anifrolumab reduced disease activity vs placebo across multiple endpoints in patients with moderately to severely active…
Abstract Number: 1830 • ACR Convergence 2020
Adverse Drug Reactions to Trimethoprim-sulfamethoxazole as a Prophylactic Agent Against Pneumocystis Pneumonia in Patients with Systemic Lupus Erythematosus: anti-Sm Antibody as a Possible Risk Factor
Shinji Izuka¹, Hiroyuki Yamashita², Yuko Takahashi² and Hiroshi Kaneko², ¹Devision of Rheumatic Disease, National Center for Global Health and Medicine, Toshima-Ku, Tokyo, Japan, ²Devision of Rheumatic Disease, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
Background/Purpose: Pneumocystis pneumonia (PCP) is a life-threatening infection in immunocompromised patients, including those with connective tissue diseases (CTDs), treated with corticosteroids or immunosuppressive agents. Trimethoprim-sulfamethoxazole…
Abstract Number: 1831 • ACR Convergence 2020
Biomarkers Linked to Anti-IFN-I and Ustekinumab Suggest Distinct Mechanism of Action in Systemic Lupus Erythematosus
Thomas Dörner¹, George Tsokos², Kenneth Kalunian³, Ronald van Vollenhoven⁴, Ashley Orillion⁵, Matteo Cesaroni⁵, Jacqueline Benson⁶, Marc Chevrier⁷, Shawn Rose⁸, Stanley Marciniak⁵, Zhenling Yao⁵, Bhaskar Srivastava⁵, Jessica Schreiter⁵, Frédéric Baribaud⁵, Tatiana Ort⁵, Jarrat Jordan⁵ and Loqmane Seridi⁵, ¹DRFZ and Charité University Hospitals, Berlin, Germany, ²Division of Rheumatology & Clinical Immunology/Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, ³University of California San Diego, La Jolla, CA, ⁴Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Research & Development, LLC, South San Francisco, CA, ⁷Janssen Research & Development, LLC, Collegeville, PA, ⁸Janssen Research & Development, LLC, Princeton Junction, NJ
Background/Purpose: Clinical and biological heterogeneity pose a significant hurdle in SLE, making biomarkers that define patient subsets crucial for developing tailored therapies. Interventional SLE trials…
Abstract Number: 1832 • ACR Convergence 2020
Barriers to Medication Adherence and Degree of Nonadherence in a Systemic Lupus Erythematosus Outpatient Population
Courtney Hardy¹, Dafna Gladman², Jiandong Su³, Nathalie Rozenbojm⁴ and Murray Urowitz⁵, ¹University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: It has been reported that 50% to 75% of patients with SLE do not adhere to their medications. However, the reasons for nonadherence are not clear.…
Abstract Number: 1833 • ACR Convergence 2020
Hydroxychloroquine and Vitamin D Both Reduce Proteinuria in SLE
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: Hydroxychloroquine (HCQ) and vitamin D are both immunomodulators in SLE, but work through different mechanisms. Hydroxychloroquine has been proven to triple renal response to…
Abstract Number: 1834 • ACR Convergence 2020
Biomarker Analysis of IFN-I Modulation in JNJ-839: First-in-Human Study for Systemic Lupus Erythematosus
Ashley Orillion¹, Loqmane Seridi¹, Matteo Cesaroni², Jessica Schreiter¹, Jacqueline Benson³, William Stohl⁴, Walter Winn Chatham⁵, Richard Alan Furie⁶, Thi-Sau Migone⁷, Stanley Marciniak¹, Zhenling Yao¹, Bhaskar Srivastava¹, Marc Chevrier² and Jarrat Jordan¹, ¹Janssen Research & Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, Spring House, ³Janssen Research & Development, LLC, South San Francisco, CA, ⁴University of Southern California Keck School of Medicine, Los Angeles, CA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁷Independent Consultant, Spring House
Background/Purpose: JNJ-839 is a fully human neutralizing antibody selective to human IFN-ω and IFN-α subtypes. Here we report the exploratory biomarker analyses of a Phase…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].